IASO BioTherapeutics（驯鹿生物）

IASO BioTherapeutics is a leading clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative cell therapies for oncology and autoimmune diseases. Leveraging its advanced fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO BioTherapeutics is at the forefront of medical innovation. The company is committed to transforming cutting-edge research into life-changing therapies.

IASO BioTherapeutics boasts a rich clinical-stage pipeline featuring multiple autologous and allogeneic CAR-T and biologics product candidates. The diversified portfolio includes 8 novel pipeline products, with the leading asset being CT103A, an innovative anti-BCMA CAR-T cell therapy. CT103A is currently under pivotal study for relapsed/refractory (R/R) multiple myeloma (RRMM) and has received Breakthrough Therapeutic Designation from China’s National Medical Products Administration (NMPA) in February 2021.

IASO BioTherapeutics continues to expand its research and development efforts, including an in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy. This therapy has received two IND clearances from NMPA for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in July 2021. IASO BioTherapeutics’ primary address is in Shanghai, CN, with an additional location in Nanjing, Jiangsu, CN. We invite the management team at IASO BioTherapeutics to create a customized and exclusive company showcase and product listing on our platform.